Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG.
Lawrence E. Flaherty
Consultant or Advisory Role - Merck; Novartis
Honoraria - Merck; Novartis
Research Funding - Merck; Novartis
James Moon
No relevant relationships to disclose
Michael B. Atkins
Consultant or Advisory Role - Bristol-Myers Squibb; Merck; Prometheus; Roche/Genentech
Ralph Tuthill
No relevant relationships to disclose
John A. Thompson
No relevant relationships to disclose
John T. Vetto
No relevant relationships to disclose
Frank G. Haluska
No relevant relationships to disclose
Alberto S. Pappo
No relevant relationships to disclose
Jeffrey Alan Sosman
No relevant relationships to disclose
Bruce G. Redman
No relevant relationships to disclose
Antoni Ribas
Consultant or Advisory Role - Amgen; Celgene; Genentech; GlaxoSmithKline; Millennium
John M. Kirkwood
Consultant or Advisory Role - Genentech; GlaxoSmithKline
Honoraria - Merck
Vernon K. Sondak
Consultant or Advisory Role - Merck
Honoraria - Merck